Jazz Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jazz Pharmaceuticals plc
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.
Both the US and EU are gradually warming up to medical marijuana, but clunky and inadequate regulation threatens to curtail the growth of a burgeoning industry.
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.